FDA Grants Accelerated Approval for Rybrevant Faspro to Treat Head and Neck Cancer
On November 5, 2026, the U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma. The approval applies specifically to patients whose cancer progressed after previous treatment with platinum-based chemotherapy and immunotherapy. It excludes patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma. This decision marks the first drug approval in 10 years for this patient population. Approval was based on trial data from 102 patients showing an overall response rate of 42 percent, meaning tumors shrank or disappeared. For 56 percent of those who responded, the response lasted six months or longer. Existing therapies are associated with response rates of 20 percent or less. Janssen Biotech, Inc. received the approval under an FDA program that requires additional confirmatory trials to verify the treatment's long-term clinical benefits.
What was announced
The U.S. Food and Drug Administration approved Rybrevant Faspro on November 5, 2026. Janssen Biotech, Inc. developed the therapy, which combines amivantamab and hyaluronidase-lpuj. The drug treats adults with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed on or after platinum-based chemotherapy and immunotherapy. It is not indicated for patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
The FDA granted approval through its Accelerated Approval Program, which uses early indicators called surrogate endpoints to evaluate drugs for serious conditions. Approval rested on overall response rate and response duration from an open-label, multicenter trial involving 102 patients. In that study, 42% of patients experienced tumor shrinkage or disappearance. Among those responders, 56% had a response lasting six months or more. The drug received Breakthrough Therapy designation. Prescribing warnings cover potential hypersensitivity reactions, lung disease, skin issues, eye toxicity, and risk to an unborn baby.
What it means
This decision brings the first new drug approval in 10 years for people with recurrent or metastatic head and neck squamous cell carcinoma who had prior platinum-based chemotherapy. This form of cancer is aggressive and life-threatening, with poor historical outcomes and limited choices once initial therapies stop working.
Currently approved options produce response rates of roughly 20% or lower. Rybrevant Faspro more than doubled that figure in trial results. Because the clearance relies on intermediate endpoints, the FDA requires Janssen Biotech, Inc. to conduct confirmatory studies. Those trials will check whether early tumor shrinkage translates into confirmed long-term clinical benefits.
What the announcement does not tell us
The announcement does not state when the drug will reach the market or what it will cost. It omits details about how many trial participants experienced specific side effects, such as lung inflammation or ocular toxicity. Additionally, the FDA did not outline the specific timelines or required patient numbers for the mandatory confirmatory trials.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap
Opens www.fda.gov
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.